Monitoring and detection of influenza, RSV, and COVID-19 in adults with and without HIV in Lusaka
Official title: Surveillance, Assessment and Detection of Influenza-Associated Respiratory Infections in HIV-Positive and HIV-Negative Individuals in Lusaka, Zambia
Run by Centre for Infectious Disease Research in Zambia · NCT07030075 · Data updated 2026-11-12
This project will test methods to detect influenza, RSV, and COVID-19 in adults with and without HIV who have recent respiratory symptoms in Lusaka.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 594 (estimated) |
| Sponsor | Centre for Infectious Disease Research in Zambia Academic / other |
| Locations | 2 sites (Lusaka, Lusaka Province and 1 other locations) |
| Status | Recruiting |
| Started | May 20, 2025 |
| Main results expected | December 2026 |
| Study ends | January 2027 |
| Registry record updated | August 5, 2026 |
| Trial ID | NCT07030075 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) in Lusaka who have had 2–7 days of flu-like or acute respiratory symptoms, are willing to share HIV and COVID-19 vaccination status, and can provide nasal/nasopharyngeal and exhaled breath samples and consent to follow-up.
✕Probably not a fit
People with symptoms for more than seven days, those unwilling to provide required samples or share HIV/COVID vaccination status, or those living outside the Lusaka clinic catchment may not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational surveillance project enrolls adults (≥18 years) presenting to two Lusaka first-level hospitals with 2–7 days of respiratory symptoms. Participants will provide nasopharyngeal swabs and exhaled breath aerosol samples, share their HIV and COVID-19 vaccination status, and complete a 7-day symptom diary with follow-up visits up to two weeks. Collected samples will be used to detect influenza, RSV, and SARS-CoV-2 to better estimate viral causes of respiratory illness and associated outcomes in this setting. The work aims to improve recognition of viral lower respiratory infections where routine viral testing is limited.
Why it matters
Potential benefit: If successful, the project could lead to earlier and more accurate detection of respiratory viruses, helping clinicians give the right care sooner.
How similar studies have gone: Previous sentinel surveillance across sub-Saharan Africa has identified influenza and other viral causes of lower respiratory infections, so the general surveillance approach is established, though routine exhaled breath aerosol sampling is less commonly used.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥18 years old * presenting with flu-like symptoms or acute respiratory infection with ≥2 to 7 days history of cough and /or sore throat and fever, +/- sneezing, +/- congestion, +/- myalgia, +/- fatigue, +/- wheezing, shortness of breath)\[55-57\] * willing to share their HIV status or be tested * willing to share their COVID-19 vaccination status * able and willing to give informed consent * willing to provide a nasal/ nasopharyngeal sample for testing as part of standard of care * willing to provide exhaled breath aerosol samples i.e. wear a mask and provide a breath sample * willing to fill a symptoms diary card for symptom tracking for 7 days * agree to be followed-up and attend study visits up to two weeks after study entry Exclusion Criteria: * individuals who are unwilling to provide any reference standard samples such as the nasopharyngeal swabs * those with symptoms for \>7 days, or * those unwilling or unable to provide informed consent
Where it's running
-
Chawama 1st level Hospital
Lusaka, Lusaka Province, Zambia Recruiting -
Kanyama 1st Level Hospital
Lusaka, Lusaka Province, Zambia Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults
This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.
-
Virological Monitoring of Seasonal Respiratory Infections in France
This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.
-
Understanding how brain changes relate to smell disorders over time
This small, year-long study tests how brain activity and smell-related inflammation relate to different smell disorders in adults.
-
Preparedness through community respiratory virus testing and engagement
This program will offer community members regular testing for respiratory viruses like COVID-19, flu, and RSV and invite some people to join longer-term monitoring and household transmission follow-up.
-
Evaluation of a new test for detecting flu and COVID-19 in patients with respiratory symptoms
This study is testing a new nasal swab test to see if it can accurately tell the difference between flu, RSV, and COVID-19 in people who have respiratory symptoms.
-
Evaluating COVID-19 and influenza vaccine schedules for immunocompromised individuals
This study is testing different ways to give COVID-19 and flu vaccines to people with weakened immune systems to see which method works best for their protection.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.